Z01 BC 011091 (Z01) | |||
---|---|---|---|
Title | Cancer Genomics Technology Development | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Meltzer, Paul | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $592,389 | Project Dates | 10/01/2007 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Neurosciences Research (20.0%) |
Brain (20.0%) Breast Cancer (40.0%) Melanoma (25.0%) Sarcoma (40.0%) Sarcoma, Bone (Sarcoma Subset) (20.0%) Sarcoma, Soft (Sarcoma Subset) (20.0%) Skin (25.0%) |
||
Research Type | |||
Technology Development and/or Marker Discovery Technology and/or Marker Evaluation With Respect to Fundamental Parameters of Method |
|||
Abstract | |||
Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution. We have applied high resolution arrays in this fashion to several systems and have also adapted this technology to the mapping of DNase I hypersensitive sites. Recently, we have demonstrated that they can be used to map DNA origins of replication. We have also worked to push the limits of detection by extending sample types to formalin fixed, paraffin embedded samples and flow sorted primary cells. We have established that useful nucleic acid preparations can be obtained from fixed tissues and are continuing to extend the analysis of this material for a wider range of genomic technologies. Current efforts have been directed primarily at the implementation of next generation sequencing technologies. These methods primarily depend on producing an array of DNA molecules which are sequentially imaged during the sequencing reaction. We are investigating the use of these methods for gene expression profiling for large and small RNAs, for the detection of genome rearrangements, mutations, and for the measurement of chromatin modifications, DNase I hypersensitive sites, and transcription factor localization. A major part of this effort is the development of a powerful computational environment which can be used to analyze the massive amount of sequence data which is generated by this work. Although this is a challenging process, it ultimately will yield a streamlined analysis pipeline in which multiple sequence based assays will be easy to integrate and free of array platform specific artifacts. |